Why Neximmune (NEXI) Stock Is Getting Hammered

Neximmune Inc (NASDAQ: NEXI) shares are trading lower by 10.2% to $3.34 Friday morning.

Neximmune Inc (NASDAQ:NEXI) shares are trading lower by 10.2% to $3.34 Friday morning. The stock is falling after the company’s Board of Directors on Thursday unanimously approved a plan to dissolve the company, contingent upon stockholder approval, while also exploring options to maximize its business and asset value.

What Else?

Neximmune plans to convene a special stockholder meeting to seek approval and will submit proxy materials to the Securities and Exchange Commission soon.

Additionally, on October 31, the Board authorized a significant reduction in the company’s workforce, except for essential management members needed for the dissolution process and value optimization efforts.

The exact cost of the reduction is uncertain at this time, but the company will update this information within four business days. The reduction is expected to be mostly completed by November 2023.

See Also: Palantir’s Q3 Beat-And-Raise ‘Another Stepping Stone Placed On The Golden Path’

According to data from Benzinga Pro, NEXI has a 52-week high of $20.35 and a 52-week low of $2.30.

Total
0
Shares
Related Posts
Read More

Zentalis To Present Clinical Data In Ovarian Cancer Combining Azenosertib And Chemotherapy, Including Clinical Support For Cyclin E1 Expression As Predictive Marker For Clinical Benefit From Azenosertib At The 2023 ASCO Annual Meeting

Builds on recent preclinical data presented at AACR supporting the use of CCNE1 amplification and / or Cyclin E1 expression as a potential marker for the enrichment of patient populations for treatment with

ZNTL